Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 2
2001 7
2002 5
2003 6
2004 4
2005 5
2006 4
2007 3
2008 9
2009 8
2010 8
2011 5
2012 6
2013 9
2014 9
2015 8
2016 6
2017 7
2018 6
2019 10
2020 4
2021 6
2022 12
2023 12
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Results by year

Filters applied: . Clear all
Page 1
Trial of Prasinezumab in Early-Stage Parkinson's Disease.
Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay JP, Mollenhauer B, López-Manzanares L, Russell DS, Boyd JT, Nicholas AP, Luquin MR, Hauser RA, Gasser T, Poewe W, Ricci B, Boulay A, Vogt A, Boess FG, Dukart J, D'Urso G, Finch R, Zanigni S, Monnet A, Pross N, Hahn A, Svoboda H, Britschgi M, Lipsmeier F, Volkova-Volkmar E, Lindemann M, Dziadek S, Holiga Š, Rukina D, Kustermann T, Kerchner GA, Fontoura P, Umbricht D, Doody R, Nikolcheva T, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. N Engl J Med. 2022 Aug 4;387(5):421-432. doi: 10.1056/NEJMoa2202867. N Engl J Med. 2022. PMID: 35921451 Clinical Trial.
Neurostimulation for Parkinson's disease with early motor complications.
Schuepbach WM, Rau J, Knudsen K, Volkmann J, Krack P, Timmermann L, Hälbig TD, Hesekamp H, Navarro SM, Meier N, Falk D, Mehdorn M, Paschen S, Maarouf M, Barbe MT, Fink GR, Kupsch A, Gruber D, Schneider GH, Seigneuret E, Kistner A, Chaynes P, Ory-Magne F, Brefel Courbon C, Vesper J, Schnitzler A, Wojtecki L, Houeto JL, Bataille B, Maltête D, Damier P, Raoul S, Sixel-Doering F, Hellwig D, Gharabaghi A, Krüger R, Pinsker MO, Amtage F, Régis JM, Witjas T, Thobois S, Mertens P, Kloss M, Hartmann A, Oertel WH, Post B, Speelman H, Agid Y, Schade-Brittinger C, Deuschl G; EARLYSTIM Study Group. Schuepbach WM, et al. N Engl J Med. 2013 Feb 14;368(7):610-22. doi: 10.1056/NEJMoa1205158. N Engl J Med. 2013. PMID: 23406026 Free article. Clinical Trial.
Reversing dopaminergic sensitization.
Castrioto A, Carnicella S, Fraix V, Chabardes S, Moro E, Krack P. Castrioto A, et al. Among authors: fraix v. Mov Disord. 2017 Dec;32(12):1679-1683. doi: 10.1002/mds.27213. Epub 2017 Nov 18. Mov Disord. 2017. PMID: 29150871 Review. No abstract available.
Long-term effects of subthalamic nucleus deep brain stimulation on speech in Parkinson's disease.
Gessani A, Cavallieri F, Fioravanti V, Campanini I, Merlo A, Di Rauso G, Damiano B, Scaltriti S, Bardi E, Corni MG, Antonelli F, Cavalleri F, Molinari MA, Contardi S, Menozzi E, Fraternali A, Versari A, Biagini G, Fraix V, Pinto S, Moro E, Budriesi C, Valzania F. Gessani A, et al. Among authors: fraix v. Sci Rep. 2023 Jul 15;13(1):11462. doi: 10.1038/s41598-023-38555-2. Sci Rep. 2023. PMID: 37454168 Free PMC article.
Surgical therapy for Parkinson's disease.
Benabid AL, Chabardès S, Seigneuret E, Fraix V, Krack P, Pollak P, Xia R, Wallace B, Sauter F. Benabid AL, et al. Among authors: fraix v. J Neural Transm Suppl. 2006;(70):383-92. doi: 10.1007/978-3-211-45295-0_58. J Neural Transm Suppl. 2006. PMID: 17017557 Review.
[Deep brain stimulation].
Fraix V, Pollak P, Chabardes S, Ardouin C, Koudsie A, Benazzouz A, Krack P, Batir A, Le Bas JF, Benabid AL. Fraix V, et al. Rev Neurol (Paris). 2004 May;160(5 Pt 1):511-21. doi: 10.1016/s0035-3787(04)70980-7. Rev Neurol (Paris). 2004. PMID: 15269668 Review. French.
Treatment results: Parkinson's disease.
Pollak P, Fraix V, Krack P, Moro E, Mendes A, Chabardes S, Koudsie A, Benabid AL. Pollak P, et al. Among authors: fraix v. Mov Disord. 2002;17 Suppl 3:S75-83. doi: 10.1002/mds.10146. Mov Disord. 2002. PMID: 11948759 Review.
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures-Cabrera J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, Simuni T, Marek K, Koller M, Sevigny J, Doody R, Fontoura P, Umbricht D, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Front Neurol. 2021 Oct 1;12:705407. doi: 10.3389/fneur.2021.705407. eCollection 2021. Front Neurol. 2021. PMID: 34659081 Free PMC article.
Pedunculopontine nucleus deep brain stimulation in Parkinson's disease: A clinical review.
Thevathasan W, Debu B, Aziz T, Bloem BR, Blahak C, Butson C, Czernecki V, Foltynie T, Fraix V, Grabli D, Joint C, Lozano AM, Okun MS, Ostrem J, Pavese N, Schrader C, Tai CH, Krauss JK, Moro E; Movement Disorders Society PPN DBS Working Groupin collaboration with the World Society for Stereotactic and Functional Neurosurgery. Thevathasan W, et al. Among authors: fraix v. Mov Disord. 2018 Jan;33(1):10-20. doi: 10.1002/mds.27098. Epub 2017 Sep 28. Mov Disord. 2018. PMID: 28960543 Review.
Results of a Randomized Clinical Trial of Speech After Early Neurostimulation in Parkinson's Disease.
Pinto S, Nebel A, Rau J, Espesser R, Maillochon P, Niebuhr O, Krack P, Witjas T, Ghio A, Cuartero MC, Timmermann L, Schnitzler A, Hesekamp H, Meier N, Müllner J, Hälbig TD, Möller B, Paschen S, Paschen L, Volkmann J, Barbe MT, Fink GR, Becker J, Reker P, Kühn AA, Schneider GH, Fraix V, Seigneuret E, Kistner A, Rascol O, Brefel-Courbon C, Ory-Magne F, Hartmann CJ, Wojtecki L, Fradet A, Maltête D, Damier P, Le Dily S, Sixel-Döring F, Benecke P, Weiss D, Wächter T, Pinsker MO, Régis J, Thobois S, Polo G, Houeto JL, Hartmann A, Knudsen K, Vidailhet M, Schüpbach M, Deuschl G; EARLYSTIM Study Group. Pinto S, et al. Among authors: fraix v. Mov Disord. 2023 Feb;38(2):212-222. doi: 10.1002/mds.29282. Epub 2022 Dec 3. Mov Disord. 2023. PMID: 36461899 Clinical Trial.
148 results